Overview

Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether pemetrexed and gemcitabine cause good tumour shrinkage when given to patients with previously untreated extensive-stage small cell lung cancer. The second purpose is to see if the side effects appear better than what is expected with standard chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Tufts Medical Center
Collaborator:
Eli Lilly and Company
Treatments:
Gemcitabine
Pemetrexed